WSPA 2019 Fall Conference

Interventional Psychiatry: A practical introduction to modern ECT, rTMS, and ketamine antidepressant therapy for established psychiatric providers

Thank You For Joining Us!

Saturday, October 19, 2019
8:00 AM–12:00 PM
Swedish Medical Center–Cherry Hill Campus, James Tower Educational Conference Center
500 17th Ave | Seattle, WA 98122
View The Presentations Materials

This training is jointly-provided by the American Psychiatric Association and the Washington State Psychiatric Association.  

The APA designates this CME activity as meeting the criteria for AMA PRA Category 1 CreditTM.

Do you want to grow your knowledge base and skills on the subject of interventional psychiatry? This program seeks to educate general practice psychiatrists in the state of Washington in the current understanding of interventional psychiatry–both well-established treatments like ECT, as well as emerging treatments like TMS and ketamine. It will utilize a large group format, as well as panel discussion. 

The practice of modern Psychiatry continues to evolve with the growing availability of novel pharmacological therapies as well as nonpharmacological, brain stimulation techniques aimed at modulating dysfunctional brain circuitry. Interventional psychiatry (IP) is an emerging subspecialty that includes expertise in novel mechanisms of psychotropic delivery, for example via intravenous or intranasal routes, as well as the use of brain stimulation techniques, such as electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation therapy (rTMS), for the treatment various neuropsychiatric conditions.  This course will serve as an introductory primer focusing on the fundamental aspects of ECT, rTMS, and ketamine antidepressant therapy for established psychiatric providers.  Through completion of this course, participants will understand how to incorporate these modalities into their treatment planning for patients as well as developed skills around: 

  1. Formulating appropriate referrals,
  2. Providing both accurate and effective pre-treatment counseling in anticipation of referral,
  3. Acknowledging and discussing stigma associated with these treatments towards enhancing openness to referral.

Featured Presenters

Brandon Kitay, MD
Assistant professor at Yale School of Medicine, Connecticut
Psychiatrist, Director of Education–Interventional Psychiatry Service, Yale-New Haven Hospital/Yale School of Medicine, New Haven CT
Sub-Investigator, Yale Depression Research Program
Consulting Psychiatrist, Yale Internal Medicine Associates - Behavioral Health Collaborative Care Program

Residency: Adult Psychiatry and Neuroscience Research Training Program (NRTP), Yale University, New Haven, CT, 2015-18, where he was Chief Resident, Interventional Psychiatry Service (IPS) and
Co-Chief Resident, Neuroscience Research Training Program (NRTP) 2017-18.
PhD: University of Miami Miller School of Medicine (Neuroscience) 2012
Medical School: MD University of Miami Miller School of Medicine 2014

Panel Members:

Anna Borisovskaya, MD
Assistant Professor, Psychiatry and Behavioral Sciences Dept, UWMC
Psychiatrist, Director of ECT Service–VA Puget Sound Health Care System (Seattle Division), Seattle WA
Director, Career Advising in Psychiatry, UWSOM

Residency: University of Washington Psychiatry Residency Training Program
Fellowship: Geriatric Psychiatry Fellowship at University of Washington
Medical School: University of Washington School of Medicine

Joshua Bess, MD
Clinical Assistant Professor, UW Psychiatry and Behavioral Sciences
Psychiatrist, Medical Director–Seattle Neuropsychiatric Treatment Center, Seattle WA
ECT Psychiatrist at Swedish Medical Center

Primary clinical interests: ECT, TMS, and other brain stimulation therapies; also pharmacotherapy of treatment-resistant mood disorders and the treatment of catatonia
Residency: University of Michigan, Inpatient Services Chief Resident
Medical School: University of Michigan

Additional information:

Dr. Bess graduated with a B.A. in Chemistry from Swarthmore College. He attended the University of Michigan for medical school and psychiatry residency where he served as Inpatient Services Chief Resident. Dr. Bess subsequently joined the faculty of the University of Michigan, Department of Psychiatry where he served as Medical Director of the Adult Inpatient Unit and Attending Physician on the Consultation-Liaison Service and the ECT Team. Dr. Bess has authored several papers and is co-author of the Manual of Inpatient Psychiatry, the second edition of which is due out next year.

Dr. Bess is a highly regarded teacher and clinician. His clinical interests include TMS, ECT and other brain stimulation therapies; also pharmacotherapy of treatment-resistant mood disorders and the treatment of catatonia.

Dr. Bess is a member of American Psychiatric Association, Washington State Psychiatric Association (current President), Association for Academic Psychiatry, Clinical TMS Society and International Society for ECT and Neurostimulation.

Zachary Fisk, MD, MBA
CEO of Acute Pain Management, PLLC
Vice President of the Washington Academy of Pain Management
Physician, Managing Director–Acute Pain Therapies, a surgical center dedicated to the comprehensive management of pain patients, Bellevue WA

Primary Clinical Interests: Ketamine for pain and psychiatric illness, perioperative nerve block and catheter placement, regenerative medicine for chronic pain in the region of the major joints (hip, knee, ankle, foot, hand, wrist, elbow, and shoulder) using PRP, peripheral nerve cryoablation, peripheral neuromodulation, and buprenorphine for pain management. He has provided ketamine infusions and generic ketamine intranasal spray for chronic pain and psychiatric illness for several years and now offers FDA approved Esketamine Nasal Spray.
Internship & Residency: University of Michigan Residency Anesthesiology 07/2009 – 06/2013
Fellowship: University of Pittsburgh – Fellowship in Acute Pain Management 07/2013 – 06/2014
Medical School: Tufts University School of Medicine 05/2005 – 06/2009

Additional information:
Dr. Fisk began his career after fellowship by creating and directing an Acute Pain Service at a local Hospital affiliated with the University of Washington, with the title of acting assistant professor, where he taught residents and, among many other things, established ketamine infusion protocols for patients in pain on surgical floors. He then created the first clinic dedicated exclusively to acute perioperative pain management in the outpatient setting. Dr. Fisk was awarded an Innovator of the Year in Pain Management Award for his efforts. He has broadened the clinic to become a highly respected treatment center for psychiatric conditions utilizing ketamine infusions as part of a broader practice that manages perioperative and chronic pain. He will focus on ketamine in his panel role.

About me:


Time Activity
7:00–8:00 am Registration & Exhibits
8:00–8:15 am Welcome/Introductions
8:15–9:00 am ECT Overview
9:00–10:00 am TMS Overview
10:00–10:15 am Break & Exhibits
10:15–11:00 am Ketamine Overview
11:00–11:15 am Break & Exhibits
11:15–12:00 pm Panel–Clinical Case Discussion


Presentations & Conference Materials

Learning Objectives

  • Define “Interventional Psychiatry” (IP) and understand its role in current clinical psychiatric practice. Participants will be able to describe the attributes of an "Interventional Psychiatry Service (IPS)" that may be adapted to various settings of clinical psychiatric care. 
  • Understand the fundamental mechanistic and technical aspects of electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS) therapy, and ketamine antidepressant therapy. Participants will become familiar with the current evidence base regarding therapeutic efficacy and the risk/benefit profile for each treatment modality towards understanding appropriate indications for referral. 
  • Describe practical clinical aspects of IP treatments including: pre-procedure counseling/work-up, elements of safe and effective procedure administration, post-procedure evaluation, and the role of the “outpatient psychiatrist” during various phases of treatment. 
  • Discuss the role of outpatient psychiatrists in mitigating stigma around- and enhancing access to- IP treatments.


Members: $105
Non-Member Physicians: $130
Nurses/Non-Physicians: $85
Psychiatry Residents (ID required): Free
Non-Psychiatry Residents (ID required): $25

You may opt to sponsor a resident for an additional $40

Registration is now closed! 
On-site registration is available.

Live vs. Virtual Attendance

Unable to attend in person? Access the meeting virtually via GoToWebinar. Registrants who select the virtual option will be provided with instructions on accessing the meeting prior to October 19. If you have any questions about this option, email the WSPA Office. We strongly suggest only using this option if you are unable to travel to Seattle and are comfortable using the technology.

Cancelation Policy

Cancellations submitted in writing on or before 10/03/2019 will receive a refund less a $25 processing fee. No refunds will be given for cancellations received after 10/03/2019.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American Psychiatric Association (APA) and Washington State Psychiatric Association. The APA is accredited by the ACCME to provide continuing medical education for physicians. The APA designates this live activity for a maximum of 3.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

 Interested in sponsoring or exhibiting? Learn more!

Platinum Sponsor

Gold Sponsors